Immune cell therapy shows promise in early trial for advanced cancers
NCT ID NCT05417750
First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 35 times
Summary
This early-phase study tested whether a treatment made from a patient's own immune cells (tumor-infiltrating lymphocytes) is safe for people with advanced solid tumors like melanoma, cervical cancer, and lung cancer. 43 participants received the therapy to find the best dose and check for side effects. The goal was to see if this personalized cell therapy can help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100039, China
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.